A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores.
Fujii T, Masuda H, Cheng YC, Yang F, Sahin AA, Naoi Y, Matsunaga Y, Raghavendra A, Sinha AK, Fernandez JRE, James A, Yamagishi K, Matsushima T, Schuetz R, Tripathy D, Tada S, Jackson RS, Noguchi S, Nakamura S, Acoba JD, Ueno NT.
Fujii T, et al. Among authors: jackson rs.
Breast Cancer Res Treat. 2021 Sep;189(2):455-461. doi: 10.1007/s10549-021-06276-7. Epub 2021 Jun 15.
Breast Cancer Res Treat. 2021.
PMID: 34131830